Shingo Takada
Hisataka Sabe2†- 1Faculty of Lifelong Sport, Department of Sports Education, Hokusho University, Ebetsu, Japan
- 2Department of Molecular Biology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
- 3Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Chronic diseases, including heart failure (HF), are often accompanied with skeletal muscle abnormalities in both quality and quantity, which are the major cause of impairment of the activities of daily living and quality of life. We have shown that skeletal muscle abnormalities are a hallmark of HF, in which metabolic pathways involving phosphocreatine and fatty acids are largely affected. Not only in HF, but the dysfunction of fatty acid metabolism may also occur in many chronic diseases, such as arteriosclerosis, as well as through insufficient physical exercise. Decreased fatty acid catabolism affects adenosine triphosphate (ATP) production in mitochondria, via decreased activity of the tricarboxylic acid cycle; and may cause abnormal accumulation of adipose tissue accompanied with hyperoxidation and ectopic lipid deposition. Such impairments of lipid metabolism are in turn detrimental to skeletal muscle, which is hence a chicken-and-egg problem between skeletal muscle and HF. In this review, we first discuss skeletal muscle abnormalities in HF, including sarcopenia; particularly their association with lipid metabolism and adipose tissue. On the other hand, the precise mechanisms involved in metabolic reprogramming and dysfunction are beginning to be understood, and an imbalance of daily nutritional intake of individuals has been found to be a causative factor for the development and worsening of HF. Physical exercise has long been known to be beneficial for the prevention and even treatment of HF. Again, the molecular mechanisms by which exercise promotes skeletal muscle as well as cardiac muscle functions are being clarified by recent studies. We propose that it is now the time to develop more “natural” methods to prevent and treat HF, rather than merely relying on drugs and medical interventions. Further analysis of the basic design of and molecular mechanisms involved in the human body, particularly the inextricable association between physical exercise and the integrity and functional plasticity of skeletal and cardiac muscles is required.
Introduction
Chronic diseases, particularly heart failure (HF), cause qualitative and quantitative abnormalities, not only in the target organ but also in distant organs, such as the skeletal muscle (1, 2). Skeletal muscle abnormalities impair the activities of daily living and the quality of life, which are major causes of the impairment of exercise tolerance and the poor prognosis of patients with HF (1). However, circulatory failure is often followed by hypoperfusion, hypoxia, inflammation, and oxidative stress, and even by an imbalance of metabolic catabolism/anabolism, aggravated muscle wasting, including cachexia, and the activation of some neurohumoral factors (1–5). Sarcopenia is also a skeletal muscle disease (6). Patients with HF often have sarcopenia, in which HF and sarcopenia cooperatively worsen skeletal muscle conditions (7) (Figure 1).
Figure 1. Summary of the association between skeletal muscle abnormalities and heart failure. Skeletal muscle abnormalities (mitochondrial dysfunction and muscular atrophy/muscular weakness) in heart failure and sarcopenia are associated with fat accumulation and abnormalities of adipokines caused by an unhealthy lifestyle, leading to reduced exercise tolerance, and a poor prognosis. QOL, quality of life; ADL, activities of daily living.
The skeletal muscle utilizes glycolysis (anaerobic) and mitochondria (aerobic) to generate adenosine triphosphate (ATP). Our research group previously demonstrated that skeletal muscle mitochondria are the major target of HF, and mitochondrial dysfunction may lead to an accumulation of lipids in the skeletal muscle (8–10). Abnormal accumulation of adipocytes then affect whole body condition (11). In this review, we first summarize our current knowledge on the abnormalities of skeletal muscle and adipose tissue in HF and sarcopenia; and then discuss possible methods to prevent and/or treat such abnormalities, as well as the exercise intolerance observed in HF.
Abnormalities of Skeletal Muscle in HF
ATP is the energy source for the contraction of skeletal muscle. However, only small amounts of ATP are present in the cytoplasm of skeletal muscle cells in the steady state (~8 mmol/kg wet weight of muscle). Needless to mention, the Embden-Myerhof glycolysis pathway generates ATP from ADP anaerobically. Skeletal muscle is rich in mitochondria, which produce ATP from ADP aerobically via oxidative phosphorylation (OXPHOS) (12, 13). On the other hand, phosphocreatine (PCr) serves as a rapidly mobilizable reserve in the skeletal muscle, as well as in the brain, to regenerate ATP from ADP anaerobically. PCr is generated from creatine by its phosphorylation, which requires ATP.
Using a cycle ergometer based on magnetic resonance spectroscopy (MRS), our research group previously measured energy metabolism of the quadriceps muscles of patients with chronic HF (unless patients did not have severe circulatory dysfunction) and healthy individuals (14, 15). We found that PCr, but not ATP, in the skeletal muscle becomes almost depleted during maximal systemic exercise both in patients and normal subjects. However, rates of the PCr decrease were significantly more rapid in patients with HF than in normal individuals, in which rates of PCr exhaustion correlated with the impairment of exercise tolerance (peak oxygen uptake and anaerobic threshold) of patients. Our results indicated that patients with HF may have impaired metabolism in their skeletal muscles, which primarily affects PCr exhaustion. The molecular bases of this rapid PCr exhaustion remains to be clarified; i.e., whether it is caused by dysfunction of PCr/creatine metabolism on its own or by insufficient production of ATP either anaerobically (glycolysis) or aerobically (mitochondrial OXPHOS). The identification of such information will then provide novel therapeutic targets of HF.
Skeletal muscle atrophy and weakness also occur in patients with HF, and correlates with their poor prognosis (16, 17). Chronic HF is generally associated with enhanced metabolic catabolism and reduced anabolism (18–26). For example, an increase in blood levels of catabolic hormones (cortisol, catecholamines, and angiotensin II) and a decrease in anabolic hormones (dehydroepiandrosterone sulfate, testosterone, and insulin-like growth factor I) have been shown to be closely associated with muscle atrophy, disease severity, and the poor prognosis of patients (18–20, 22). In particular, testosterone is tightly linked to exercise tolerance (22), and the efficacy of testosterone replacement therapy has been proven in various clinical trials. However, as testosterone often shows side effects, nonsteroidal androgen receptor agonists are being studied (27, 28). On the other hand, in a mouse HF model, molecules of the ubiquitin-proteasome system (atrogin 1 and muscle RING-finger protein-1) were shown to be upregulated and to cause further muscle atrophy (29). Moreover, skeletal muscle cell death is enhanced in patients with HF (29). Together with the above issues, therefore, both the qualitative (metabolic impairment) and quantitative (muscular atrophy) abnormalities of the skeletal muscle are hallmarks of patients with HF (Figure 1).
Sarcopenia and Cachexia in HF
Sarcopenia was previously defined as a “syndrome” in 2010 (30), but is now recognized as a “skeletal muscle disease” (6). On the other hand, the diagnostic criteria of the Asian Sarcopenia Working Group includes lean limb mass and lean skeletal muscle mass (31). Furthermore, in the European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic HF, sarcopenia is defined as follows (32).
“Skeletal muscle wasting, when associated with impaired mobility and symptoms (termed sarcopenia or myopenia), occurs in 30–50% of patients with the HF reduced ejection fraction (HFrEF) (33). In its most severe form, it is associated with frailty and poor morbidity and mortality (34). Potential treatments may include appetite stimulants, exercise training (35), and anabolic agents, including testosterone, in combination with the application of nutritional supplements, and anti-catabolic interventions, although none is of proven benefit and their safety is unknown” (36).
Sarcopenia worsens HF (7). Pathologically, there is a crucial difference between HF and sarcopenia, i.e., HF results in a decrease in slow muscle fibers (oxidative fibers), whereas sarcopenia results in a decrease in fast muscle fibers (fast glycolytic fibers). Moreover, sarcopenia lacks any early diagnostic markers (37). In a study of 200 patients with HF in which 39 patients (19.5%) had sarcopenia, oxygen uptake (exercise capacity), 6-min walking distance, left ventricular ejection fraction, grip strength, and quadriceps strength were all significantly lower in the patients with sarcopenia than in those without sarcopenia (33). Another study also suggested a higher risk of mortality in patients with HF with sarcopenia, by further reducing the peak oxygen uptake (38). On the other hand, cachexia is accompanied by a loss of body weight (fat, skeletal muscle, and bone tissue), loss of appetite, and loss of body composition and function (39). Cachexia thus shares significant similarities with sarcopenia, and can be considered as a secondary sarcopenia. It was reported that there is a loss of skeletal muscle mass without a loss of body weight (sarcopenia) in early HF, which is often followed by a loss of body weight (cachexia) (40). Therefore, the occurrence of cachexia in patients with HF is a biomarker predictive for an increase in severity of chronic HF (16). However, the molecular links among sarcopenia, cachexia, and HF, with regard to the precise molecular/biochemical mechanisms, still remain largely elusive (Figure 1).
Adipose Tissues and Fatty Acids in HF
White Adipose Tissue (WAT) and Brown Adipose Tissue (BAT)
Adipose tissues are crucial in regulating cardiovascular functions, primarily through the secretion of adipocytokines controlling the cardiovascular endocrine and paracrine systems (11).
WAT is an endocrine organ that secretes adipokines, besides its role as an energy store (41, 42). When obesity occurs, it often triggers the secretion of adipokines, as well as induces inflammatory responses, leading to insulin resistance of the skeletal muscle and liver (11). Our previous studies have shown that patients with obesity or metabolic syndrome demonstrate an accumulation of visceral fats and white adipocytes, as well as systemic insulin resistance and the dysfunction of skeletal muscle mitochondria (10, 43–49). Intriguingly, patients with chronic HF and mouse HF models also demonstrate systemic insulin resistance (50–52). However, the molecular details as to how systemic insulin resistance often occurs in patients with HF still await to be clarified.
Shimizu et al. (53–55) have recently demonstrated that chronic inflammation in visceral fat causes systemic insulin resistance and exacerbates HF. They showed that visceral fat inflammation in patients with HF is caused by enhanced sympathetic nerve signaling, excessive fat melting, the production of reactive oxygen species (ROS), and the DNA damage-induced activation of the p53-nuclear factor-kappa B pathway. Blockade of this pathway suppressed visceral fat inflammation and improved systemic insulin resistance and cardiac function. Moreover, systemic insulin resistance may also be associated with mitochondrial dysfunction in the skeletal muscle (43–46, 48, 49, 56).
BAT is important for body heat production (57). However, recent studies demonstrated the more profound roles of BAT as a center controlling glucose and lipid metabolism of the whole body (58–63). On the other hand, impairment of BAT in obesity increases the number of lipid droplets and reduces the amount of mitochondria in BAT cells (i.e., “whitening” of BAT) (64). In contrast, when vascular endothelial growth factor α is expressed in the whitening BAT, its “rebrowning” occurs, which helps to improve insulin resistance of the whole body (64). These changes are reversible (64). Furthermore, low body temperature is an independent marker of the poor outcome of patients with HF and a reduced EF (65). Moreover, a decrease in body temperature predicts the time of rehospitalization and poor survival rate (66). Therefore, BAT impairment is also crucial to the worsening of HF, for which the precise molecular mechanisms await to be clarified.
Ectopic Fat Deposition in the Skeletal Muscle of Patients With HF
Mechanisms by which cardiovascular diseases progress include the loss of metabolic balance between glycolipid synthesis and energy consumption in insulin-sensitive organs (67). On the other hand, the ectopic deposition of fats, which is causative of cardiovascular diseases, may also occur regardless of glucose/insulin tolerance (68). Moreover, ectopic fat deposition in tissues other than the heart (e.g., pericardial fats), including skeletal muscle, is also thought to be involved in HF pathology (11, 69) (Figure 1).
Reduced fatty acid oxidation in skeletal muscle mitochondria was observed in HF animal models (70–72). Using proton MRS, we measured intramyocellular lipid (IMCL) levels; and found that it is significantly increased in the skeletal muscle of patients with HF compared with healthy subjects, and is hence closely associated with lowered skeletal muscle energy metabolism and reduced whole-body exercise tolerance (8). Consistently, levels of three-hydroxyacyl-CoA dehydrogenase, a key enzyme of β-oxidation, were significantly reduced in the skeletal muscle of patients with HF and of an animal model (70, 71, 73, 74). Such skeletal muscle abnormalities of HF mice were shown to associate with systemic insulin resistance (50–52). Likewise, the amounts of IMCL in skeletal muscles were associated with insulin resistance in type 2 diabetic patients (75). In this disease, exercise therapy and diet therapy reduced lipid droplet levels and improved insulin resistance (43). Therefore, adequate exercise and a proper diet appear to be an efficient method to treat HF and associated insulin resistance (Figure 1).
Targeting Skeletal Muscle Abnormalities in HF Therapy
The following are possible interventions for patients with HF via lifestyle improvement (exercise/diet), drugs (exercise mimetics), and proteins/peptides, to improve the integrity of their skeletal muscle and adipose tissue.
Lifestyle Interventions
Exercise Training
Continuous exercise training, including cardiac rehabilitation, has many beneficial effects to treat heart diseases (76). Endurance or resistance training of patients with HF is recommended by the American Heart Association and the Japanese Circulation Society (77, 78). Recently, moderate to high intensity interval training has been studied as an exercise prescription of HF (79, 80), as alternatives to anaerobic (about 90% of the maximum heart rate) and/or aerobic exercises (81). Elucidation of these effects and mechanisms will help further develop more precise exercise prescriptions for HF.
Lipids, Particularly Linoleic Acid
Higher levels of plasma eicosapentaenoic acid, an essential omega-3 fatty acid, is closely associated with a reduced risk of HF, with both reduced and preserved EF (82). On the other hand, the combined supplementation of l-alanyl-l-glutamine and polyunsaturated fatty acids has been shown not to improve exercise performance or muscle function (83). Linoleic acid is an essential omega-6 fatty acid and is the major fatty acid moiety of cardiolipin, which is central to the assembly of mitochondrial OXPHOS components. We found that cardiolipin content in cardiac mitochondria becomes significantly lower in HF model mice, to be consistent with lowered OXPHOS activities (84). We thus fed HF model mice with a relatively high amount of linoleic acid (~6 mg/kg body weight/day) in their daily food for 4 weeks; and found that such an amount of daily intake of linoleic acid improves both mitochondrial and cardiac functions of HF mice, in which the assembly of the complex II subunits and the complex III2/complex IV supercomplex of mitochondrial OXPHOS were improved. Consistent with our results, a recent prospective study also demonstrated that a high linoleic acid concentration in blood is associated with a lower risk of HF incidence in aged men (85). On the other hand, it should be noted that an excess intake of linoleic acid is well-known to be harmful to health, such as by causing arteriosclerosis (86). However, ironically, we found that among the different fatty acids, only the dietary intake of linoleic acid is significantly lower in New York Heart Association (NYHA) class III patients compared with class II patients (84).
Interventions Using a Device or Surgery
Cardiac resynchronization therapy, a left ventricular assist device, and percutaneous transluminal mitral commissurotomy, ameliorate hemodynamics immediately after surgery for HF, but do not immediately improve exercise intolerance and take longer than exercise training (87–89). This suggests that skeletal muscle abnormalities mediate hemodynamics and exercise tolerance, and further studies should be performed to clarify this point in the future.
Drug Treatment Using Exercise Mimetics
Available Pharmacological Treatments
Renin-angiotensin system (RAS) inhibitors
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers (ARBs), antihypertensive drugs can help improve skeletal muscle abnormalities and the exercise intolerance of patients with HF (90). We have shown previously that excessive ROS production induced by activating RAS in skeletal muscle is a possible mechanism causing skeletal muscle abnormalities in HF mice (50–52); and demonstrated that (pro)renin receptor inhibitors, a decoy peptide of the handle region of mouse (pro)renin, and ARBs can improve insulin resistance, including in the skeletal muscle of HF mice (50–52). We also showed that the administration of angiotensin II, the main effector molecule of the RAS, induces similar skeletal muscle abnormalities to HF, which can be improved by inhibiting NAD(P)H-derived ROS production (91, 92).
Dipeptidyl peptidase 4 (DPP-4) inhibitor and glucagon-like peptide-1 (GLP-1)
Treatment with the incretin hormone GLP-1 (93) was reported to improve exercise intolerance of patients with HF (94). We analyzed whether the DPP-4 inhibitor, which increases GLP-1 levels (95), as well as an agonist against the GLP-1 receptor, improves skeletal muscle abnormalities and exercise intolerance in HF model mice. Our results indicated that these drugs are effective in improving mitochondrial biogenesis in the skeletal muscle of HF mice, in which lowered exercise capacity and mitochondrial function/volume, and altered fiber types of skeletal muscles (a shift toward the fast-twitch fiber type) are restored to a certain extent, without notably affecting infarct size and cardiac function (74).
Sodium-glucose cotransporter 2 (SGLT2) inhibitors
SGLT2 is a transporter that is expressed in the proximal tubules of the kidneys and reabsorbs ~90% of glomerular filtered glucose. SGLT2 inhibitors promote urinary glucose excretion, resulting in hypoglycemic and weight-loss effects independent of insulin action. The SGLT2 inhibitor ipragliflozin improved fatty liver syndrome of ob/ob obese mice fed a high-fat diet (96). This suggests that the increased energy storage capacity of adipocytes may be associated with the suppression of ectopic fat accumulation in the liver. On the other hand, treatment with an SGLT2 inhibitor was shown to alleviate disease progression, including the death of patients with HF with a reduced EF regardless of the presence or absence of diabetes (97). Our recent study showed that the SGLT2 inhibitor empagliflozin improves fatty acid oxidation in skeletal muscle mitochondria of HF mice (71). However, molecular links between SGLT2 and HF still remain largely elusive.
Endocrine Factors
Myokines
Epidemiological studies have shown that continuous physical exercise exerts a variety of medical benefits throughout the body and contributes to prolonging the lifespan of an individual (98). More than 10 years ago, it was reported that various hormone-like bioactive substances are secreted from the skeletal muscle. Pedersen et al. (99) suggested that cytokines and other peptides that are produced, expressed, and released by muscle fibers and exert either paracrine or endocrine effects should be classified as “myokines.” Very interestingly, brain-derived neurotrophic factor (BDNF) is secreted from the skeletal muscle upon physical exercise and is thus categorized as a myokine (100). We found that serum levels of BDNF were significantly lower in patients with HF than healthy subjects (101). Univariate analysis demonstrated a significant positive correlation between serum BDNF levels and peak VO2 (oxygen uptake) among all study subjects, including patients with HF (101). By multivariate analysis, peak VO2 was identified as an independent determinant of serum BDNF level (99). We have moreover shown that low levels of serum BDNF statistically correlate with the poor outcomes of patients with HF (102). Decreased skeletal muscle BDNF correlated with decreased exercise capacity in HF model mice (70). We designed a treatment to improve the impaired exercise capacity as well as the dysfunction of skeletal muscle mitochondria of myocardial infarction (MI) mice. At 2 weeks after inducing MI, we divided mice into two groups: one was treated with recombinant human BDNF (rhBDNF) by daily subcutaneous injections for an additional 2 weeks, and the other was injected with empty vehicle. At 4 weeks, (i.e., after 2 weeks of treatment), we found that the rhBDNF-treated MI mice demonstrated improved cardiac mitochondrial respiration and exercise intolerance compared with control MI mice (70). Molecularly, rhBDNF increased mitochondrial biogenesis and fatty acid oxidation via the upregulation of AMP-activated protein kinase (AMPK) α-peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) signaling in skeletal muscle (70). Our studies were the first to show that BDNF expression is decreased in the skeletal muscle of HF mice after the induction of MI, and that rhBDNF improves exercise capacity and skeletal muscle mitochondrial dysfunction of the HF mice.
Apelin is another myokine produced by skeletal muscle upon physical exercise that is beneficial against exercise tolerance (103). Serum levels of apelin are also reduced in an age-dependent manner in humans and rodents. Mice deficient in either apelin or its receptor demonstrated substantial alterations in muscle function during aging. Molecularly, apelin promotes mitochondrial biogenesis, autophagy, and anti-inflammatory responses of myofibers, and also enhances the regeneration potential of muscle stem cells. Therefore, similar to BDNF, apelin can be used to diagnose early sarcopenia, and provides an excellent therapeutic target to prevent age-associated muscle weakness (103).
Myonectin is a myokine that is upregulated in skeletal muscle and blood by exercise (104). Myonectin is an endurance exercise-induced myokine that ameliorates acute myocardial ischemic injury by suppressing apoptosis and inflammation in the heart (105). Likewise, BDNF protects against cardiac dysfunction after MI (106). Thus, these data suggest that myonectin and BDNF are myokines that mediate the beneficial actions of exercise on cardiovascular health.
Adipokines
Adiponectin is an antidiabetic adipokine. Its receptors possess a seven-transmembrane topology with the amino terminus located intracellularly, which is opposite to that of G-protein-coupled receptors. Iwabu et al. provided lines of evidence that adiponectin induces extracellular Ca2+ influx via adiponectin receptor 1 (AdipoR1), which is necessary for the subsequent activation of Ca2+/calmodulin-dependent protein kinase kinase b (CaMKKb), AMPK, and sirtuin1 (SIRT1), the increase in expression and decrease in acetylation of PGC-1α, and increase in myocyte mitochondrial number. Moreover, muscle-specific disruption of AdipoR1 suppressed the adiponectin-mediated increase in intracellular Ca2+ concentration, and decreased the activation of CaMKK, AMPK, and SIRT1 by adiponectin. The suppression of AdipoR1 also resulted in a decrease in PGC-1α expression and deacetylation, decrease in mitochondrial content, and decrease in oxidative type I fibers, and a decrease in oxidative stress-detoxifying enzymes in skeletal muscle, which were associated with insulin resistance and decreased exercise endurance. Decreased levels of adiponectin and AdipoR1 in obesity may have causative roles in the mitochondrial dysfunction and insulin resistance observed in diabetes (107).
Paralogs of adiponectin, such as C1q/tumor necrosis factor-related protein 9 in adipokines protect against acute cardiac damage in response to pathological stimuli (e.g., lipopolysaccharides) and myocardial ischemia-reperfusion, by suppressing inflammation through the AdipoR1/AMPK-dependent pathway (108, 109). Therefore, adiponectin in particular has protective effects, in not only skeletal muscle but also in the heart.
Hepatokines
It is well-known that the responsiveness to physical exercise differs markedly among different people. “Exercise resistance” is considered to be congenital, with no evidence of acquired causative factors. The antioxidative hepatokine selenoprotein P (SeP) was shown to cause exercise resistance through its muscle receptor, low-density lipoprotein receptor-related protein 1 (LRP1) (110). SeP-deficient mice showed a “super-endurance” phenotype after exercise training, which was accompanied by enhanced ROS production, AMPK phosphorylation, and PGC-1α expression in skeletal muscle. Supplementation with the antioxidant N-acetylcysteine reduced ROS production and endurance capacity in SeP-deficient mice. SeP treatment impaired hydrogen peroxide-induced adaptations through LRP1 in cultured myotubes and suppressed exercise-induced AMPK phosphorylation and Ppargc1a gene expression in mouse skeletal muscle, and these effects were inhibited in mice with muscle-specific LRP1 deficiency. Furthermore, increased amounts of circulating SeP predicted the ineffectiveness of training on endurance capacity in humans. Thus, it was proposed that inhibitors of the SeP-LRP1 axis may function as exercise-enhancing drugs for the treatment of diseases associated with a sedentary lifestyle (110).
Osteokines
Aerobic exercise was recently shown to increase blood levels of osteocalcin, which is produced by osteoblasts, in mice and humans, whereas blood osteocalcin decreases during aging in mice, monkeys, and humans (111). On the other hand, patients with cachexia owing to chronic HF have decreased bone mineral content (112). Whether exercise training (cardiac rehabilitation) of patients with HF can improve osteokine levels awaits to be determined.
Senolytics
Cellular senescence induces the senescence-associated secretory phenotype, which causes chronic inflammation and contributes to the acceleration of aging of an individual. Recently, senolytic drugs have been developed to remove senescent cells; a senolytic cocktail (dasatinib and quercetin) decreases naturally occurring senescent cells and their secretion of frailty-associated proinflammatory cytokines in human adipose tissues (113). It was also shown that such senolytics can enhance healthspan, as well as lifespan, of aged mice (113).
A Blood Cell Biomarker to Assess Skeletal/Cardiac Muscle Abnormalities
The mitochondrial function of monocytes, a peripheral blood mononuclear cell (PBMC), provides a possible method to assess skeletal and cardiac mitochondrial function (114). We also reported that the mitochondrial function of PBMCs is decreased in patients with HF, and is associated with disease severity and increased mitochondrial ROS (115). Intriguingly, we moreover demonstrated that mitochondrial ROS levels of PBMCs are closely associated with systemic exercise tolerance (115).
Conclusion and Future Perspectives
In this review, we discussed the pathology of skeletal muscle abnormalities in HF, including fat accumulation and dysfunction of adipose tissues. Recent advancements in this research field have demonstrated an inseparable association between skeletal muscle abnormalities and adipose tissues of animals with HF, in which these abnormalities can be both the causes and results of HF. Thus, these abnormalities can be therapeutic targets to treat HF, because skeletal muscle and adipose tissue are readily used for clinical testing and diagnoses, as well as for therapeutic interventions; whereas cardiac muscle are difficult to be engineered (Figure 1).
On the other hand, our understanding of the precise molecular and biochemical association between these abnormalities and HF remains incomplete. In particular, given that skeletal muscle abnormalities are frequent in the chronic phase of HF and that such abnormalities are crucial to the worsening of HF, it is very important to identify biomarkers that predict the onset of muscle abnormalities in HF, as well as the molecular mechanisms involved therein. Moreover, as we have discussed above, sarcopenia is also closely associated with HF, with regard to abnormalities of the skeletal muscle and the adipose tissue. Again, there remain a lot to be clarified regarding the molecular and biochemical bases of the association between skeletal/cardiac muscle abnormalities and HF (Figure 1).
Lastly, adequate levels of daily physical exercise are very effective for preventing HF, and are also effective for the treatment of HF. Not only does physical exercise enhance systemic blood circulation and lymphatic flow, which are both crucial for individual immunity, but physical exercise produces myokines in the peripheral blood stream that improve the condition of skeletal muscle mitochondria and maybe also the nervous system, as stated earlier. Analysis of skeletal muscle biopsies has shown that exercise therapy is effective in curing HF with preserved EF patients by repairing skeletal muscle abnormalities and improving exercise tolerance (116–122). A deeper and more precise molecular understanding of our body and its basic design, which has been formed during our evolution on this planet, namely, “HUMAN BIOLOGY,” will help toward developing “natural” methods with minimal medical interventions, rather than developing conservative drugs as HF therapeutics, as well as for the prevention of HF.
Author Contributions
ST, HS, and SK wrote the manuscript.
Funding
This work was supported in part by grants from the Japanese Grants-In-Aid for Scientific Research [JP17H04758 (to ST) and 18H03187 (to SK)], Grants-in-Aid for Challenging Exploratory Research [19K22791 (to ST), the Japan Foundation for Applied Enzymology (to ST)], and JST COI Grant Number JPMJCE1301 (to ST).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Kinugawa S, Takada S, Matsushima S, Okita K, Tsutsui H. Skeletal muscle abnormalities in heart failure. Int Heart J. (2015) 56:475–84. doi: 10.1536/ihj.15-108
2. Okita K, Kinugawa S, Tsutsui H. Exercise intolerance in chronic heart failure–skeletal muscle dysfunction and potential therapies. Circ J. (2013) 77:293–300. doi: 10.1253/circj.CJ-12-1235
3. Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol. (1996) 28:1092–102. doi: 10.1016/S0735-1097(96)00323-3
4. Franssen FM, Wouters EF, Schols AM. The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr. (2002) 21:1–14. doi: 10.1054/clnu.2001.0485
5. Middlekauff HR. Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail. (2010) 3:537–46. doi: 10.1161/CIRCHEARTFAILURE.109.903773
6. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. (2019) 48:16–31. doi: 10.1093/ageing/afy169
7. Onoue Y, Izumiya Y, Hanatani S, Tanaka T, Yamamura S, Kimura Y, et al. A simple sarcopenia screening test predicts future adverse events in patients with heart failure. Int J Cardiol. (2016) 215:301–6. doi: 10.1016/j.ijcard.2016.04.128
8. Hirabayashi K, Kinugawa S, Yokota T, Takada S, Fukushima A, Suga T, et al. Intramyocellular lipid is increased in the skeletal muscle of patients with dilated cardiomyopathy with lowered exercise capacity. Int J Cardiol. (2014) 176:1110–2. doi: 10.1016/j.ijcard.2014.07.113
9. Nakano I, Hori H, Fukushima A, Yokota T, Kinugawa S, Takada S, et al. Enhanced echo intensity of skeletal muscle is associated with exercise intolerance in patients with heart failure. J Card Fail. (in press). doi: 10.1016/j.cardfail.2019.09.001
10. Yokota T, Kinugawa S, Hirabayashi K, Suga T, Takada S, Omokawa M, et al. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. J Diabetes Investig. (2017) 8:535–41. doi: 10.1111/jdi.12606
11. Oikonomou EK, Antoniades C. The role of adipose tissue in cardiovascular health and disease. Nat Rev Cardiol. (2019) 16:83–99. doi: 10.1038/s41569-018-0097-6
12. Rasmussen UF, Rasmussen HN, Krustrup P, Quistorff B, Saltin B, Bangsbo J. Aerobic metabolism of human quadriceps muscle: in vivo data parallel measurements on isolated mitochondria. Am J Physiol Endocrinol Metab. (2001) 280:E301–7. doi: 10.1152/ajpendo.2001.280.2.E301
13. Maekawa S, Takada S, Furihata T, Fukushima A, Yokota T, Kinugawa S. Mitochondrial respiration of complex II is not lower than that of complex I in mouse skeletal muscle. Biochem Biophys Rep. (2020) 21:100717. doi: 10.1016/j.bbrep.2019.100717
14. Okita K, Yonezawa K, Nishijima H, Hanada A, Ohtsubo M, Kohya T, et al. Skeletal muscle metabolism limits exercise capacity in patients with chronic heart failure. Circulation. (1998) 98:1886–91. doi: 10.1161/01.CIR.98.18.1886
15. Okita K, Nishijima H, Yonezawa K, Ohtsubo M, Hanada A, Kohya T, et al. Skeletal muscle metabolism in maximal bicycle and treadmill exercise distinguished by using in vivo metabolic freeze method and phosphorus-31 magnetic resonance spectroscopy in normal men. Am J Cardiol. (1998) 81:106–9. doi: 10.1016/S0002-9149(97)00857-6
16. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. (1997) 349:1050–3. doi: 10.1016/S0140-6736(96)07015-8
17. Hulsmann M, Quittan M, Berger R, Crevenna R, Springer C, Nuhr M, et al. Muscle strength as a predictor of long-term survival in severe congestive heart failure. Eur J Heart Fail. (2004) 6:101–7. doi: 10.1016/j.ejheart.2003.07.008
18. Dalla Libera L, Vescovo G, Volterrani M. Physiological basis for contractile dysfunction in heart failure. Curr Pharm Des. (2008) 14:2572–81. doi: 10.2174/138161208786071254
19. Anker SD, Volterrani M, Pflaum CD, Strasburger CJ, Osterziel KJ, Doehner W, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol. (2001) 38:443–52. doi: 10.1016/S0735-1097(01)01385-7
20. Schulze PC, Spate U. Insulin-like growth factor-1 and muscle wasting in chronic heart failure. Int J Biochem Cell Biol. (2005) 37:2023–35. doi: 10.1016/j.biocel.2005.04.017
21. Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlomagno G, Imbriaco M, et al. Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab. (2009) 94:3329–36. doi: 10.1210/jc.2009-0533
22. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. (2006) 114:1829–37. doi: 10.1161/CIRCULATIONAHA.106.649426
23. Adams V, Bowen TS, Werner S, Barthel P, Amberger C, Konzer A, et al. Small-molecule-mediated chemical knock-down of MuRF1/MuRF2 and attenuation of diaphragm dysfunction in chronic heart failure. J Cachexia Sarcopenia Muscle. (2019) 10:1102–15. doi: 10.1002/jcsm.12448
24. Bacurau AV, Jannig PR, de Moraes WM, Cunha TF, Medeiros A, Barberi L, et al. Akt/mTOR pathway contributes to skeletal muscle anti-atrophic effect of aerobic exercise training in heart failure mice. Int J Cardiol. (2016) 214:137–47. doi: 10.1016/j.ijcard.2016.03.071
25. Heineke J, Auger-Messier M, Xu J, Sargent M, York A, Welle S, et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation. (2010) 121:419–25. doi: 10.1161/CIRCULATIONAHA.109.882068
26. Okutsu M, Call JA, Lira VA, Zhang M, Donet JA, French BA, et al. Extracellular superoxide dismutase ameliorates skeletal muscle abnormalities, cachexia, and exercise intolerance in mice with congestive heart failure. Circ Heart Fail. (2014) 7:519–30. doi: 10.1161/CIRCHEARTFAILURE.113.000841
27. Bendayan M, Bibas L, Levi M, Mullie L, Forman DE, Afilalo J. Therapeutic interventions for frail elderly patients: part II Ongoing and unpublished randomized trials. Prog Cardiovasc Dis. (2014) 57:144–51. doi: 10.1016/j.pcad.2014.07.005
28. Bhattacharya I, Tarabar S, Liang Y, Pradhan V, Owens J, Oemar B. Safety pharmacokinetic, and pharmacodynamic evaluation after single and multiple ascending doses of a novel selective androgen receptor modulator in healthy subjects. Clin Ther. (2016) 38:1401–16. doi: 10.1016/j.clinthera.2016.03.025
29. von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol. (2017) 14:323–41. doi: 10.1038/nrcardio.2017.51
30. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in older people. Age Ageing. (2010) 39:412–23. doi: 10.1093/ageing/afq034
31. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. (2014) 15:95–101. doi: 10.1016/j.jamda.2013.11.025
32. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis treatment of acute chronic heart failure: the task force for the diagnosis treatment of acute chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. (2016) 37:2129–200. doi: 10.1093/eurheartj/ehw128
33. Fulster S, Tacke M, Sandek A, Ebner N, Tschope C, Doehner W, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. (2013) 34:512–9. doi: 10.1093/eurheartj/ehs381
34. Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, epidemiology-update 2014. J Cachexia Sarcopenia Muscle. (2014) 5:253–9. doi: 10.1007/s13539-014-0161-y
35. Piepoli MF, Conraads V, Corra U, Dickstein K, Francis DP, Jaarsma T, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail. (2011) 13:347–57. doi: 10.1093/eurjhf/hfr017
36. von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. J Am Med Dir Assoc. (2014) 15:866–72. doi: 10.1016/j.jamda.2014.09.007
37. Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. (2016) 7:512–4. doi: 10.1002/jcsm.12147
38. Kamiya K, Masuda T, Matsue Y, Hamazaki N, Matsuzawa R, Tanaka S, et al. Prognostic usefulness of arm and calf circumference in patients >/=65 years of age with cardiovascular disease. Am J Cardiol. (2017) 119:186–91. doi: 10.1016/j.amjcard.2016.09.040
39. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. (2008) 27:793–9. doi: 10.1016/j.clnu.2008.06.013
40. von Haehling S. The wasting continuum in heart failure: from sarcopenia to cachexia. Proc Nutr Soc. (2015) 74:367–77. doi: 10.1017/S0029665115002438
41. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. (1993) 259:87–91. doi: 10.1126/science.7678183
42. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. (2011) 11:85–97. doi: 10.1038/nri2921
43. Suga T, Kinugawa S, Takada S, Kadoguchi T, Fukushima A, Homma T, et al. Combination of exercise training and diet restriction normalizes limited exercise capacity and impaired skeletal muscle function in diet-induced diabetic mice. Endocrinology. (2014) 155:68–80. doi: 10.1210/en.2013-1382
44. Takada S, Hirabayashi K, Kinugawa S, Yokota T, Matsushima S, Suga T, et al. Pioglitazone ameliorates the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice. Eur J Pharmacol. (2014) 740:690–6. doi: 10.1016/j.ejphar.2014.06.008
45. Takada S, Kinugawa S, Hirabayashi K, Suga T, Yokota T, Takahashi M, et al. Angiotensin II receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice. J Appl Physiol (1985). (2013) 114:844–57. doi: 10.1152/japplphysiol.00053.2012
46. Takada S, Kinugawa S, Matsushima S, Takemoto D, Furihata T, Mizushima W, et al. Sesamin prevents decline in exercise capacity and impairment of skeletal muscle mitochondrial function in mice with high-fat diet-induced diabetes. Exp Physiol. (2015) 100:1319–30. doi: 10.1113/EP085251
47. Yokota T, Kinugawa S, Okita K, Hirabayashi K, Suga T, Hattori M, et al. Lower aerobic capacity was associated with abnormal intramuscular energetics in patients with metabolic syndrome. Hypertens Res. (2011) 34:1029–34. doi: 10.1038/hr.2011.78
48. Yokota T, Kinugawa S, Hirabayashi K, Matsushima S, Inoue N, Ohta Y, et al. Oxidative stress in skeletal muscle impairs mitochondrial respiration and limits exercise capacity in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. (2009) 297:H1069–77. doi: 10.1152/ajpheart.00267.2009
49. Yokota T, Kinugawa S, Yamato M, Hirabayashi K, Suga T, Takada S, et al. Systemic oxidative stress is associated with lower aerobic capacity and impaired skeletal muscle energy metabolism in patients with metabolic syndrome. Diabetes Care. (2013) 36:1341–6. doi: 10.2337/dc12-1161
50. Fukushima A, Kinugawa S, Takada S, Matsumoto J, Furihata T, Mizushima W, et al. Direct renin inhibitor ameliorates insulin resistance by improving insulin signaling and oxidative stress in the skeletal muscle from post-infarct heart failure in mice. Eur J Pharmacol. (2016) 779:147–56. doi: 10.1016/j.ejphar.2016.03.022
51. Fukushima A, Kinugawa S, Takada S, Matsushima S, Sobirin MA, Ono T, et al. (Pro)renin receptor in skeletal muscle is involved in the development of insulin resistance associated with postinfarct heart failure in mice. Am J Physiol Endocrinol Metab. (2014) 307:E503–14. doi: 10.1152/ajpendo.00449.2013
52. Ohta Y, Kinugawa S, Matsushima S, Ono T, Sobirin MA, Inoue N, et al. Oxidative stress impairs insulin signal in skeletal muscle and causes insulin resistance in postinfarct heart failure. Am J Physiol Heart Circ Physiol. (2011) 300:H1637–44. doi: 10.1152/ajpheart.01185.2009
53. Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest. (2010) 120:1506–14. doi: 10.1172/JCI40096
54. Shimizu I, Yoshida Y, Moriya J, Nojima A, Uemura A, Kobayashi Y, et al. Semaphorin3E-induced inflammation contributes to insulin resistance in dietary obesity. Cell Metab. (2013) 18:491–504. doi: 10.1016/j.cmet.2013.09.001
55. Shimizu I, Yoshida Y, Katsuno T, Tateno K, Okada S, Moriya J, et al. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab. (2012) 15:51–64. doi: 10.1016/j.cmet.2011.12.006
56. Sergi D, Naumovski N, Heilbronn LK, Abeywardena M, O'Callaghan N, Lionetti L, et al. Mitochondrial (Dys)function and insulin resistance: from pathophysiological molecular mechanisms to the impact of diet. Front Physiol. (2019) 10:532. doi: 10.3389/fphys.2019.00532
57. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. (1998) 92:829–39. doi: 10.1016/S0092-8674(00)81410-5
58. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med. (2011) 17:200–5. doi: 10.1038/nm.2297
59. Nedergaard J, Cannon B. The changed metabolic world with human brown adipose tissue: therapeutic visions. Cell Metab. (2010) 11:268–72. doi: 10.1016/j.cmet.2010.03.007
60. Long JZ, Svensson KJ, Bateman LA, Lin H, Kamenecka T, Lokurkar IA, et al. The secreted enzyme PM20D1 regulates lipidated amino acid uncouplers of mitochondria. Cell. (2016) 166:424–35. doi: 10.1016/j.cell.2016.05.071
61. Stanford KI, Middelbeek RJ, Goodyear LJ. Exercise effects on white adipose tissue: beiging and metabolic adaptations. Diabetes. (2015) 64:2361–8. doi: 10.2337/db15-0227
62. Svensson KJ, Long JZ, Jedrychowski MP, Cohen P, Lo JC, Serag S, et al. A secreted slit2 fragment regulates adipose tissue thermogenesis and metabolic function. Cell Metab. (2016) 23:454–66. doi: 10.1016/j.cmet.2016.01.008
63. Wang GX, Zhao XY, Meng ZX, Kern M, Dietrich A, Chen Z, et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nat Med. (2014) 20:1436–43. doi: 10.1038/nm.3713
64. Shimizu I, Aprahamian T, Kikuchi R, Shimizu A, Papanicolaou KN, MacLauchlan S, et al. Vascular rarefaction mediates whitening of brown fat in obesity. J Clin Invest. (2014) 124:2099–112. doi: 10.1172/JCI71643
65. Payvar S, Spertus JA, Miller AB, Casscells SW, Pang PS, Zannad F, et al. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. Eur J Heart Fail. (2013) 15:1382–9. doi: 10.1093/eurjhf/hft113
66. Ahmed A, Aboshady I, Munir SM, Gondi S, Brewer A, Gertz SD, et al. Decreasing body temperature predicts early rehospitalization in congestive heart failure. J Card Fail. (2008) 14:489–96. doi: 10.1016/j.cardfail.2008.02.008
67. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab. (2003) 14:398–403. doi: 10.1016/j.tem.2003.09.008
68. Shimabukuro M, Kozuka C, Taira S, Yabiku K, Dagvasumberel M, Ishida M, et al. Ectopic fat deposition and global cardiometabolic risk: new paradigm in cardiovascular medicine. J Med Invest. (2013) 60:1–14. doi: 10.2152/jmi.60.1
69. Nakajima T, Yokota T, Shingu Y, Yamada A, Iba Y, Ujihira K, et al. Impaired mitochondrial oxidative phosphorylation capacity in epicardial adipose tissue is associated with decreased concentration of adiponectin and severity of coronary atherosclerosis. Sci Rep. (2019) 9:3535. doi: 10.1038/s41598-019-40419-7
70. Matsumoto J, Takada S, Kinugawa S, Furihata T, Nambu H, Kakutani N, et al. Brain-derived neurotrophic factor improves limited exercise capacity in mice with heart failure. Circulation. (2018) 138:2064–6. doi: 10.1161/CIRCULATIONAHA.118.035212
71. Nambu H, Takada S, Fukushima A, Matsumoto J, Kakutani N, Maekawa S, et al. Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure. Eur J Pharmacol. (2020) 866:172810. doi: 10.1016/j.ejphar.2019.172810
72. Tsuda M, Fukushima A, Matsumoto J, Takada S, Kakutani N, Nambu H, et al. Protein acetylation in skeletal muscle mitochondria is involved in impaired fatty acid oxidation and exercise intolerance in heart failure. J Cachexia Sarcopenia Muscle. (2018) 9:844–59. doi: 10.1002/jcsm.12322
73. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation. (1990) 81:518–27. doi: 10.1161/01.CIR.81.2.518
74. Takada S, Masaki Y, Kinugawa S, Matsumoto J, Furihata T, Mizushima W, et al. Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling. Cardiovasc Res. (2016) 111:338–47. doi: 10.1093/cvr/cvw182
75. Tamura Y, Tanaka Y, Sato F, Choi JB, Watada H, Niwa M, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. (2005) 90:3191–6. doi: 10.1210/jc.2004-1959
76. Witt BJ, Jacobsen SJ, Weston SA, Killian JM, Meverden RA, Allison TG, et al. Cardiac rehabilitation after myocardial infarction in the community. J Am Coll Cardiol. (2004) 44:988–96. doi: 10.1016/j.jacc.2004.05.062
77. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. (2013) 128:873–934. doi: 10.1161/CIR.0b013e31829b5b44
78. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure - digest version. Circ J. (2019) 83:2084–184. doi: 10.1253/circj.CJ-19-0342
79. Malmo V, Nes BM, Amundsen BH, Tjonna AE, Stoylen A, Rossvoll O, et al. Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. Circulation. (2016) 133:466–73. doi: 10.1161/CIRCULATIONAHA.115.018220
80. Rognmo O, Moholdt T, Bakken H, Hole T, Molstad P, Myhr NE, et al. Cardiovascular risk of high- versus moderate-intensity aerobic exercise in coronary heart disease patients. Circulation. (2012) 126:1436–40. doi: 10.1161/CIRCULATIONAHA.112.123117
81. Meyer P, Gayda M, Juneau M, Nigam A. High-intensity aerobic interval exercise in chronic heart failure. Curr Heart Fail Rep. (2013) 10:130–8. doi: 10.1007/s11897-013-0130-3
82. Block RC, Liu L, Herrington DM, Huang S, Tsai MY, O'Connell TD, et al. Predicting risk for incident heart failure with omega-3 fatty acids: from MESA. JACC Heart Fail. (2019) 7:651–61. doi: 10.1016/j.jchf.2019.03.008
83. Wu C, Kato TS, Ji R, Zizola C, Brunjes DL, Deng Y, et al. Supplementation of l-alanyl-l-glutamine and fish oil improves body composition and quality of life in patients with chronic heart failure. Circ Heart Fail. (2015) 8:1077–87. doi: 10.1161/CIRCHEARTFAILURE.115.002073
84. Maekawa S, Takada S, Nambu H, Furihata T, Kakutani N, Setoyama D, et al. Linoleic acid improves assembly of the CII subunit and CIII2/CIV complex of the mitochondrial oxidative phosphorylation system in heart failure. Cell Commun Signal. (2019) 17:128. doi: 10.1186/s12964-019-0445-0
85. Wannamethee SG, Jefferis BJ, Lennon L, Papacosta O, Whincup PH, Hingorani AD. Serum conjugated linoleic acid and risk of incident heart failure in older men: the British regional heart study. J Am Heart Assoc. (2018) 7:e006653. doi: 10.1161/JAHA.117.006653
86. Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ. (2013) 346:e8707. doi: 10.1136/bmj.e8707
87. Yasu T, Katsuki T, Ohmura N, Nakada I, Owa M, Fujii M, et al. Delayed improvement in skeletal muscle metabolism and exercise capacity in patients with mitral stenosis following immediate hemodynamic amelioration by percutaneous transvenous mitral commissurotomy. Am J Cardiol. (1996) 77:492–7. doi: 10.1016/S0002-9149(97)89343-5
88. Patwala AY, Woods PR, Sharp L, Goldspink DF, Tan LB, Wright DJ. Maximizing patient benefit from cardiac resynchronization therapy with the addition of structured exercise training: a randomized controlled study. J Am Coll Cardiol. (2009) 53:2332–9. doi: 10.1016/j.jacc.2009.02.063
89. Rogers JG, Aaronson KD, Boyle AJ, Russell SD, Milano CA, Pagani FD, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol. (2010) 55:1826–34. doi: 10.1016/j.jacc.2009.12.052
90. Conraads VM, Van Craenenbroeck EM, De Maeyer C, Van Berendoncks AM, Beckers PJ, Vrints CJ. Unraveling new mechanisms of exercise intolerance in chronic heart failure: role of exercise training. Heart Fail Rev. (2013) 18:65–77. doi: 10.1007/s10741-012-9324-0
91. Kadoguchi T, Kinugawa S, Takada S, Fukushima A, Furihata T, Homma T, et al. Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle. Exp Physiol. (2015) 100:312–22. doi: 10.1113/expphysiol.2014.084095
92. Kadoguchi T, Takada S, Yokota T, Furihata T, Matsumoto J, Tsuda M, et al. Deletion of NAD(P)H oxidase 2 prevents angiotensin ii-induced skeletal muscle atrophy. Biomed Res Int. (2018) 2018:3194917. doi: 10.1155/2018/3194917
93. Drucker DJ. The biology of incretin hormones. Cell Metab. (2006) 3:153–65. doi: 10.1016/j.cmet.2006.01.004
94. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. (2006) 12:694–9. doi: 10.1016/j.cardfail.2006.08.211
95. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. (2005) 48:141–51. doi: 10.1021/jm0493156
96. Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One. (2016) 11:e0151511. doi: 10.1371/journal.pone.0151511
97. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure reduced ejection fraction. N Engl J Med. (2019) 381:1995–2008. doi: 10.1056/NEJMoa1911303
98. Samitz G, Egger M, Zwahlen M. Domains of physical activity and all-cause mortality: systematic review and dose-response meta-analysis of cohort studies. Int J Epidemiol. (2011) 40:1382–400. doi: 10.1093/ije/dyr112
99. Pedersen BK, Akerstrom TC, Nielsen AR, Fischer CP. Role of myokines in exercise and metabolism. J Appl Physiol (1985). (2007) 103:1093–8. doi: 10.1152/japplphysiol.00080.2007
100. Matthews VB, Astrom MB, Chan MH, Bruce CR, Krabbe KS, Prelovsek O, et al. Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia. (2009) 52:1409–18. doi: 10.1007/s00125-009-1364-1
101. Fukushima A, Kinugawa S, Homma T, Masaki Y, Furihata T, Yokota T, et al. Decreased serum brain-derived neurotrophic factor levels are correlated with exercise intolerance in patients with heart failure. Int J Cardiol. (2013) 168:e142–4. doi: 10.1016/j.ijcard.2013.08.073
102. Fukushima A, Kinugawa S, Homma T, Masaki Y, Furihata T, Yokota T, et al. Serum brain-derived neurotropic factor level predicts adverse clinical outcomes in patients with heart failure. J Card Fail. (2015) 21:300–6. doi: 10.1016/j.cardfail.2015.01.003
103. Vinel C, Lukjanenko L, Batut A, Deleruyelle S, Pradere JP, Le Gonidec S, et al. The exerkine apelin reverses age-associated sarcopenia. Nat Med. (2018) 24:1360–71. doi: 10.1038/s41591-018-0131-6
104. Seldin MM, Peterson JM, Byerly MS, Wei Z, Wong GW. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. (2012) 287:11968–80. doi: 10.1074/jbc.M111.336834
105. Otaka N, Shibata R, Ohashi K, Uemura Y, Kambara T, Enomoto T, et al. Myonectin is an exercise-induced myokine that protects the heart from ischemia-reperfusion injury. Circ Res. (2018) 123:1326–38. doi: 10.1161/CIRCRESAHA.118.313777
106. Okada S, Yokoyama M, Toko H, Tateno K, Moriya J, Shimizu I, et al. Brain-derived neurotrophic factor protects against cardiac dysfunction after myocardial infarction via a central nervous system-mediated pathway. Arterioscler Thromb Vasc Biol. (2012) 32:1902–9. doi: 10.1161/ATVBAHA.112.248930
107. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. (2010) 464:1313–9. doi: 10.1038/nature08991
108. Kambara T, Shibata R, Ohashi K, Matsuo K, Hiramatsu-Ito M, Enomoto T, et al. C1q/tumor necrosis factor-related protein 9 protects against acute myocardial injury through an adiponectin receptor I-AMPK-dependent mechanism. Mol Cell Biol. (2015) 35:2173–85. doi: 10.1128/MCB.01518-14
109. Kambara T, Ohashi K, Shibata R, Ogura Y, Maruyama S, Enomoto T, et al. CTRP9 protein protects against myocardial injury following ischemia-reperfusion through AMP-activated protein kinase (AMPK)-dependent mechanism. J Biol Chem. (2012) 287:18965–73. doi: 10.1074/jbc.M112.357939
110. Misu H, Takayama H, Saito Y, Mita Y, Kikuchi A, Ishii KA, et al. Deficiency of the hepatokine selenoprotein P increases responsiveness to exercise in mice through upregulation of reactive oxygen species and AMP-activated protein kinase in muscle. Nat Med. (2017) 23:508–16. doi: 10.1038/nm.4295
111. Mera P, Laue K, Ferron M, Confavreux C, Wei J, Galan-Diez M, et al. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab. (2016) 23:1078–92. doi: 10.1016/j.cmet.2016.05.004
112. Anker SD, Clark AL, Teixeira MM, Hellewell PG, Coats AJ. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol. (1999) 83:612–5, A10. doi: 10.1016/S0002-9149(98)00927-8
113. Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. (2018) 24:1246–56. doi: 10.1038/s41591-018-0092-9
114. Tyrrell DJ, Bharadwaj MS, Jorgensen MJ, Register TC, Molina AJ. Blood cell respirometry is associated with skeletal and cardiac muscle bioenergetics: implications for a minimally invasive biomarker of mitochondrial health. Redox Biol. (2016) 10:65–77. doi: 10.1016/j.redox.2016.09.009
115. Shirakawa R, Yokota T, Nakajima T, Takada S, Yamane M, Furihata T, et al. Mitochondrial reactive oxygen species generation in blood cells is associated with disease severity and exercise intolerance in heart failure patients. Sci Rep. (2019) 9:14709. doi: 10.1038/s41598-019-51298-3
116. Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. Circ Heart Fail. (2015) 8:286–94. doi: 10.1161/CIRCHEARTFAILURE.114.001825
117. Kitzman DW, Nicklas B, Kraus WE, Lyles MF, Eggebeen J, Morgan TM, et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol. (2014) 306:H1364–70. doi: 10.1152/ajpheart.00004.2014
118. Sarma S, Levine BD. Soothing the sleeping giant: improving skeletal muscle oxygen kinetics and exercise intolerance in HFpEF. J Appl Physiol (1985). (2015) 119:734–8. doi: 10.1152/japplphysiol.01127.2014
119. Upadhya B, Haykowsky MJ, Eggebeen J, Kitzman DW. Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. J Geriatr Cardiol. (2015) 12:294–304. doi: 10.1007/s11897-015-0257-5
120. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail. (2010) 3:659–67. doi: 10.1161/CIRCHEARTFAILURE.110.958785
121. Haykowsky MJ, Brubaker PH, Stewart KP, Morgan TM, Eggebeen J, Kitzman DW. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. J Am Coll Cardiol. (2012) 60:120–8. doi: 10.1016/j.jacc.2012.02.055
Keywords: mitochondria, ectopic fat, sarcopenia/cachexia, peripheral blood mononuclear cell, myokine, exercise
Citation: Takada S, Sabe H and Kinugawa S (2020) Abnormalities of Skeletal Muscle, Adipocyte Tissue, and Lipid Metabolism in Heart Failure: Practical Therapeutic Targets. Front. Cardiovasc. Med. 7:79. doi: 10.3389/fcvm.2020.00079
Received: 27 February 2020; Accepted: 15 April 2020;
Published: 12 May 2020.
Edited by:
Yuichi J. Shimada, Columbia University Irving Medical Center, United StatesReviewed by:
Rei Shibata, Nagoya University Hospital, JapanWai Ho Tang, Guangzhou Women and Children's Medical Center, China
Copyright © 2020 Takada, Sabe and Kinugawa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shingo Takada, s-takada@hotmail.co.jp
†These authors have contributed equally to this work